VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
VRAXVirax Biolabs Group Limited
$3.35$581821
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksVRAXCash Flow

Virax Biolabs Group Limited (VRAX) Cash Flow Statement

6Y historyFree accessUpdated daily

The firm continues to burn capital at an alarming rate, evidenced by a 2025Q4 free cash flow margin of -2177.7% and a capital expenditure-to-revenue ratio of 258.3% in the same period.

VRAX Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMMar'25Mar'24Mar'23Mar'22Mar'21Mar'20
Cash from Operations-10.09M-4.56M-6.25M-4.18M-809.07K-590.19K-744.61K
Operating CF Margin %--72083.02%-3993.77%-48823.35%--476.65%-745.54%
Operating CF Growth %-43.97%26.95%-49.46%-416.61%-37.09%20.74%-
Net Income-12.22M-6.07M-6.74M-5.46M-1.71M-650.98K-739.46K
Depreciation & Amortization645.47K343.39K103.1K0000
Stock-Based Compensation1.56M365.31K1.01M1.73M290.36K00
Deferred Taxes0000000
Other Non-Cash Items318.84K169.34K497.06K-260.6K-32.07K1.19K91.67K
Working Capital Changes-382.46K625.62K-1.12M-216.28K644.39K59.61K-96.82K
Change in Receivables-179.53K219.66K-217.84K0928-9280
Change in Inventory-29.68K-34.29K-60.38K20.95K121-21.07K0
Change in Payables-669.63K466.85K-572.25K33.94K641.16K81.61K-96.82K
Cash from Investing-1.2M-603.89K-1.16M-178.4K000
Capital Expenditures-1.21M-603.89K-952.5K-178.4K000
CapEx % of Revenue1371.89%9538.62%608.94%2083.9%---
Acquisitions0000000
Investments-------
Other Investing3.65K0-211.95K-178.4K000
Cash from Financing9.53M5.81M1.65M13.69M813.21K585.2K704.64K
Debt Issued (Net)-82.36K-107.76K-206.27K146.25K100K00
Equity Issued (Net)7.9M5.13M23413.65M519.61K00
Dividends Paid0000000
Share Repurchases-85.5K000000
Other Financing1.71M786.74K1.85M-111.64K193.59K585.2K704.64K
Net Change in Cash-1.76M639.7K-5.76M9.33M4.13K-4.99K-39.97K
Free Cash Flow-11.48M-5.17M-7.41M-4.36M-809.07K-590.19K-744.61K
FCF Margin %-13068.41%-81621.64%-4738.21%-50907.25%--476.65%-745.54%
FCF Growth %-26.81%30.28%-70.06%-438.66%-37.09%20.74%-
FCF per Share-2.41-1.67-3.69-4.10-0.71-0.52-0.65
FCF Conversion (FCF/Net Income)0.94x0.75x0.93x0.77x0.47x0.91x0.93x
Interest Paid5.79K78.95K00000
Taxes Paid0000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Existential liquidity and solvency

Persistent Disconnect Between Earnings Reality

As reported in recent financial filings, VRAX exhibits a persistent divergence between net income and operating cash flow, with OCF/NI ratios frequently exceeding 1.0, suggesting that non-cash charges and working capital volatility are masking the true extent of the company's underlying cash-based operational losses.

The recurring pattern of operating cash flow being more negative than net income implies that the company is struggling with cash-based outflows that are not fully captured by accounting accruals. Investors should monitor whether this trend indicates hidden cash-burn drivers beyond the reported income statement figures.

Free Cash Flow Trajectory Remains Negative

Based on quarterly cash flow statements, VRAX has consistently generated negative free cash flow, with margins reaching as low as -2177.7% in 2025Q4, indicating that the firm lacks a self-sustaining business model capable of covering its operational and capital expenditure requirements through internal cash generation.

The trajectory of free cash flow suggests an accelerating depletion of liquidity, as the company fails to achieve the scale necessary to offset its fixed cost base. This persistent cash drain warrants further investigation into the company's remaining runway and potential reliance on dilutive financing.

Capital Intensity Outpacing Revenue Generation

According to historical data, VRAX's capital expenditure relative to revenue has reached extreme levels, such as 258.3% in 2025Q4, which suggests that the company is investing in infrastructure or assets that are failing to produce any meaningful top-line growth or commercial return.

High capital intensity in the absence of revenue growth may indicate inefficient asset deployment or the maintenance of legacy infrastructure that no longer serves the current business strategy. This capital allocation appears to be value-destructive given the lack of corresponding revenue expansion.

Working Capital Volatility Signals Inefficiency

As evidenced by the provided cash flow statements, VRAX experiences significant swings in working capital, including a $623.5K outflow in 2026Q2, which suggests that the company is struggling to manage its inventory and receivables effectively in a declining market environment.

The erratic nature of working capital changes may reflect difficulties in clearing obsolete inventory or collecting on stagnant distribution agreements. Such volatility often serves as a leading indicator of operational distress and poor supply chain management.

Stock-Based Compensation Obscures Cash Reality

Based on reported financial statements, VRAX has utilized stock-based compensation, including $925.7K in 2024Q4, to manage its cash position, a practice that effectively shifts the burden of operational losses onto shareholders through dilution rather than addressing the core business's inability to generate cash.

The reliance on non-cash compensation suggests that management is attempting to preserve limited cash reserves at the expense of equity value. This strategy may provide temporary relief but does not resolve the fundamental lack of commercial viability inherent in the current business model.

VRAX — Frequently Asked Questions

Quick answers to the most common questions about buying VRAX stock.

How much cash does Virax Biolabs Group Limited (VRAX) generate from operations?

Virax Biolabs Group Limited (VRAX) generated $-4.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Virax Biolabs Group Limited's free cash flow?

Virax Biolabs Group Limited (VRAX) reported negative free cash flow of $5.2M in 2025, indicating capital requirements exceeded cash from operations.

What is Virax Biolabs Group Limited's capital expenditure (CapEx)?

Virax Biolabs Group Limited (VRAX) spent $0.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.